Participated · Series A · Apr 2025

Phantom Neuro develops a minimally invasive neural interface platform called Phantom X to enable intuitive control of prosthetic limbs and robotic exoskeletons. Phantom X, originally developed at the Johns Hopkins University School of Medicine, is designed to restore natural movement by making assistive devices function as seamless extensions of the body. The company reported that its ASCENT study demonstrated 94% accuracy decoding real-time gestures across 11 essential hand and wrist movements. Phantom Neuro has received FDA Breakthrough Device and TAP designations for Phantom X, which may expedite regulatory approvals. The company plans to use new funding to accelerate preclinical testing, complete first-in-human trials, pursue regulatory submissions, and expand R&D for broader control applications beyond prosthetic limbs. Phantom Neuro is headquartered in Austin, Texas and has raised $28 million in total funding to date. Phantom Neuro develops a low-power, high-accuracy system intended to provide lifelike control of robotic orthopedic technologies. The company is positioned in the neurotech sector and is based in Austin, TX. Its core product targets control interfaces for robotic orthopedics, emphasizing low power consumption and high accuracy. The article does not disclose operating metrics such as revenue or user counts. Phantom Neuro announced a $6 million expanded seed financing, which increases its total funding to $9.5 million. The funding supports the company’s continued development of its control system for robotic orthopedic applications. Phantom Neuro is a neurotechnology company based in Austin, Texas and Baltimore, Maryland that is creating a system to enable lifelike control of robotic orthopedic technologies such as prosthetic limbs and exoskeletons. Its solution combines low-risk implantable sensors, AI, and enabling software to provide control of existing and next-generation orthopedic devices. The company is led by founder and CEO Dr. Connor Glass. Phantom Neuro raised seed funding to expand its operations and business reach. The $3.26M round was led by LionBird Ventures with participation from Draper Associates, Breakout Ventures, Blackrock Neurotech, Capital Factory, and private investors. As part of the financing, LionBird partner Robert Lord will join the board and LionBird Managing Partner Ed Michael will join as a board observer.

Participated · Series A · Dec 2024

Fluid Biomed is a clinical-stage medical device company based in Calgary, Alberta, developing ReSolv™, the world’s first bioabsorbable polymer-based neurovascular stent for brain aneurysms. The ReSolv™ stent has been validated by years of scientific research and demonstrated functional benefits in a first-in-human clinical study. The technology was developed by co-founders John Wong, M.D. (CEO), and Alim Mitha, M.D. (President and CTO), both academic neurosurgeons at the University of Calgary. The company plans to use recent financing to further validate the ReSolv™ stent and its proprietary delivery system in expanded patient studies and to enable larger clinical trials. Fluid Biomed also intends to broaden its product pipeline with the additional strategic and financial capital. Fluid Biotech is commercializing a hybrid polymer-metal flow-diverting brain stent constructed of bioabsorbable polymer and metal to provide a scaffold that enables better healing and vessel visualization. Led by Dr. John Wong (CEO) and Dr. Alim Mitha (President and CTO), the company aims to cure intracranial aneurysms with this novel device. Fluid closed a $4.7M seed funding round to advance development. The company intends to use the funds to engage contract manufacturers to initiate production, complete regulatory milestones, and plan for first-in-human implantation. In conjunction with the raise, Fluid added two board members with capital and industry experience to support commercialization and regulatory progress. The company is based in Calgary, Alberta, Canada.

Participated · Series B · Jun 2021

Synchron is a New York City–based neurotechnology company building the Stentrode platform, an endovascular brain-computer interface (BCI) that is delivered via catheter rather than open-brain surgery. Once implanted, the device interfaces with the motor cortex through the blood vessels and wirelessly transmits neural signals that can be translated into hands-free digital commands. Ten patients with paralysis have received the Stentrode across U.S. and Australian clinical trials, demonstrating early clinical adoption. Led by founder and CEO Tom Oxley, the company plans to use newly raised capital to scale operations and advance product development. Synchron’s ultimate goal is to commercialize a clinically viable, minimally invasive BCI for widespread medical use. Including the latest round, the company has secured $345 million in total funding to date, underlining strong investor confidence in its technology and market potential.